Validation of GCN5L1/BLOC1S1/BLOS1 antibodies using knockout cells and tissue.
Paramesha Bugga, Michael W Stoner, Janet R Manning, Bellina A S Mushala, Nisha Bhattarai, Maryam Sharifi-Sanjani, Bradley R Webster, Dharendra Thapa, Iain Scott
Article in The Biochemical journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Paramesha Bugga *Vascular Medicine Institute, University of Pittsburgh, Pittsburgh, PA 15261, U.S.A.
Michael W Stoner *Vascular Medicine Institute, University of Pittsburgh, Pittsburgh, PA 15261, U.S.A.
Janet R ManningVascular Medicine Institute, University of Pittsburgh, Pittsburgh, PA 15261, U.S.A.
Bellina A S MushalaVascular Medicine Institute, University of Pittsburgh, Pittsburgh, PA 15261, U.S.A.
Nisha BhattaraiVascular Medicine Institute, University of Pittsburgh, Pittsburgh, PA 15261, U.S.A.
Maryam Sharifi-SanjaniVascular Medicine Institute, University of Pittsburgh, Pittsburgh, PA 15261, U.S.A.
Bradley R WebsterDepartment of Urology, Roswell Park Cancer Center, Buffalo, NY 14263, U.S.A.
Dharendra ThapaDepartment of Human Performance - Exercise Physiology, West Virginia University, Morgantown, WV 26506, U.S.A.
Iain ScottVascular Medicine Institute, University of Pittsburgh, Pittsburgh, PA 15261, U.S.A.ORCID 0000-0001-5929-0928
Funding
Novel strategies to resolve metabolic defects in the diabetic heartR01HL147861 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI SCOTT, IAIN · 2020 to 2024
$2.4M
Fatty acid oxidation in female cardioprotectionR01HL156874 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI SCOTT, IAIN · 2022 to 2025
$2.2M
Regulation of Fuel Utilization by Lysine Acetylation in the Failing HeartR01HL132917 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI SCOTT, IAIN · 2017 to 2020
$1.9M
Predoctoral Training in Pharmacological Sciences (Resubmission)T32GM133332 · NIGMS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Tija C. Jacob, Francisco Jose Schopfer · 2020 to 2026
$1.8M
Investigating the novel role of acetylation in cardiac mitochondrial bioenergetics and function in the aging heartR00HL146905 · NHLBI · WEST VIRGINIA UNIVERSITY · PI THAPA, DHARENDRA · 2021 to 2023
$747k
Regulation of Fuel Utilization by Lysine Acetylation in the Failing HeartR56HL132917 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI SCOTT, IAIN · 2016 to 2016
$469k
Investigating the novel role of acetylation in cardiac mitochondrial bioenergetics and function in the aging heartK99HL146905 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI THAPA, DHARENDRA · 2020 to 2021
$346k
Targeting the hepatic adropin signaling pathway in obesityF31DK134089 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI MUSHALA, BELLINA · 2023 to 2023
GCN5L1, also known as BLOC1S1 and BLOS1, is a small intracellular protein involved in many key biological processes. Over the last decade, GCN5L1 has been implicated in the regulation of protein lysine acetylation, energy metabolism, endo-lysosomal function, and cellular immune pathways. An increasing number of published papers have used commercially-available reagents to interrogate GCN5L1 function. However, in many cases these reagents have not been rigorously validated, leading to potentially misleading results. In this report we tested several commercially-available antibodies for GCN5L1, and found that two-thirds of those available did not unambiguously detect the protein by western blot in cultured mouse cells or ex vivo liver tissue. These data suggest that previously published studies which used these unverified antibodies to measure GCN5L1 protein abundance, in the absence of other independent methods of corroboration, should be interpreted with appropriate caution.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
Validation of GCN5L1/BLOC1S1/BLOS1 antibodies using knockout cells and tissue. · full record | Socratic